Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
Status:
RECRUITING
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn whether chlorpromazine and promethazineC+Pis safe in Acute Ischemic StrokeAIS) patients and determine the maximum dosage. It will also evaluate the preliminary efficacy of C+P in AIS. The main questions it aims to answer are:
What is the optimal dosage of C+P that is safe without causing adverse effects in AIS patients? What is the optimal dosage of C+P that potentially works to treat AIS? Researchers will compare C+P with placebo (saline solution without C+P) to see if C+P is safe and effective in treating Acute Ischemic Stroke.
Participants will:
Receive C+P or placebo at the same time as endovascular thrombectomy begins. Patients will be observed for 72 hours to see if there were any adverse effects related to C+P. Infarct volumes will be evaluated using Computed Tomography. Functional outcomes will be assessed at 90 days.